Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOY · Real-Time Price · USD
2.670
-0.060 (-2.20%)
At close: Sep 11, 2026, 4:00 PM EDT
2.830
+0.160 (6.00%)
After-hours: Sep 11, 2026, 7:56 PM EDT
Decoy Therapeutics Revenue
Decoy Therapeutics had revenue of $227.63K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $227.63K.
Revenue (ttm)
$227.63K
Revenue Growth
n/a
P/S Ratio
7.69
Revenue / Employee
$20,694
Employees
11
Market Cap
1.75M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 1.84M | -3.39M | -64.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 27.82M |
| Curis | 4.31M |
| Jupiter Neurosciences | 64.69K |
| Endovia Health Sciences | 32.09K |
| Virax Biolabs Group | 12.42K |
| Valion Bio | -86.00K |
DCOY News
- 4 days ago - Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference - Newsfile Corp
- 4 weeks ago - Decoy Therapeutics Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Decoy Therapeutics Proxy statement: Proxy filing - Filings
- 5 weeks ago - Decoy Therapeutics Proxy statement: Proxy filing - Filings
- 5 weeks ago - Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform - PRNewsWire
- 6 weeks ago - Decoy Therapeutics’ D-MAV platform shows inhibition of Ebola Zaire virus - TheFly
- 6 weeks ago - Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats - PRNewsWire
- 7 weeks ago - Decoy Therapeutics Proxy statement: Proxy filing - Filings